Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission
NCT02140255Phase 2Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2015
- Primary completion
- Jan 2028
- Countries
- 13
01
Overview
A Phase 2 trial of nevirapine, lopinavir + ritonavir, raltegravir, VRC01, dolutegravir in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Started Jan 2015; status: recruiting.
02
Drugs
nevirapinelopinavir + ritonavirraltegravirVRC01dolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02140255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02140255.